phrykt

Neurogene Inc. (NGNE): who owns it and who trades it

As of Nov 16, 2026, NGNE insiders reported 17 open-market sales worth $1.1M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christine Mikail Cvijic (CFO), with $900K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Neurogene

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NGNE

113 funds and institutions reported NGNE shares worth $546M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Samsara Biocapital, LLC with 11.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Samsara Biocapital, LLC11.0%
Casdin Capital, LLC9.9%
Redmile Group, LLC9.1%
Rtw Investments, LP8.7%
EcoR1 Capital, LLC8.2%
BlackRock, Inc.6.8%
Baker Bros. Advisors LP6.4%
Balyasny Asset Management L.P.5.3%
Trails Edge Capital Partners, LP4.6%
Toronto Dominion Bank4.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Samsara Biocapital, LLC1.72M11.03%$54MNo change
Casdin Capital, LLC1.55M9.92%$48.6M+9%
Redmile Group, LLC1.41M9.07%$44.4M-3%
Rtw Investments, LP1.36M8.75%$42.8MNo change
EcoR1 Capital, LLC1.27M8.16%$40MNo change
BlackRock, Inc.1.06M6.79%$33.3M+5%
Baker Bros. Advisors LP991,6916.37%$31.2MNo change
Balyasny Asset Management L.P.818,7065.26%$25.7M+14%
Trails Edge Capital Partners, LP714,8854.59%$22.5M-9%
Toronto Dominion Bank681,3374.37%$21.4MNo change
Vanguard Capital Management LLC536,5253.44%$16.9M+4%
Jennison Associates LLC518,5823.33%$16.3M-2%
Citadel Advisors LLC408,9822.63%$12.9M+6%
Great Point Partners LLC352,1802.26%$11.1M-30%
ArrowMark Colorado Holdings LLC342,4532.20%$10.8M-35%
FMR LLC (Fidelity)295,5611.90%$9.3M-23%
Geode Capital Management, LLC293,1821.88%$9.2M+5%
State Street Corp224,3221.44%$7.1M-28%
Franklin Resources Inc204,2801.31%$6.4MNew
Morgan Stanley191,7241.23%$6M-33%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, NGNE insiders reported $0 of open-market purchases and $1.1M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1.1M
17 trades, 4 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Jul 7, 2026
Filed Jul 7, 2026

Purchases and sales by month

$373K$373KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 7, 2026Christine Mikail CvijicCFOSale plan4,200$36.13$152KForm 4
Jul 6, 2026Christine Mikail CvijicCFOSale plan600$36.02$21.6KForm 4
Jul 2, 2026Christine Mikail CvijicCFOSale plan2,531$34.58$87.5KForm 4
Jul 2, 2026Christine Mikail CvijicCFOSale plan1,530$35.23$53.9KForm 4
Jul 1, 2026Christine Mikail CvijicCFOSale plan739$34.06$25.2KForm 4
May 6, 2026Christine Mikail CvijicCFOSale plan4,800$32.44$156KForm 4
May 6, 2026Christine Mikail CvijicCFOSale plan4,800$30.07$144KForm 4
Mar 26, 2026Christine Mikail CvijicCFOSale plan2,558$21.62$55.3KForm 4
Mar 26, 2026Rachel McMinnCEOSale plan3,352$22.07$74KForm 4
Mar 26, 2026Julie JordanChief Medical OfficerSale plan828$21.89$18.1KForm 4
Mar 13, 2026Stuart CobbChief Scientific OfficerSale plan2,658$21.34$56.7KForm 4
Mar 13, 2026Stuart CobbChief Scientific OfficerSale plan3,991$20.41$81.5KForm 4
Mar 13, 2026Stuart CobbChief Scientific OfficerSale plan148$22.08$3.3KForm 4
Mar 13, 2026Christine Mikail CvijicCFOSale plan263$22.02$5.8KForm 4
Mar 13, 2026Christine Mikail CvijicCFOSale plan1,395$21.25$29.6KForm 4
Mar 13, 2026Christine Mikail CvijicCFOSale plan2,387$20.42$48.7KForm 4
Feb 27, 2026Christine Mikail CvijicCFOSale plan4,800$25.11$121KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Christine Mikail CvijicPresident and CFO–$900KJul 7, 2026
Stuart CobbChief Scientific Officer–$141KMar 13, 2026
Rachel McMinnChief Executive Officer, Director–$74KMar 26, 2026
Julie JordanChief Medical Officer–$18.1KMar 26, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NGNE short interest

Very high short interest. 28.4% of NGNE shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 58%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.69M NGNE shares were sold short, 28.4% of the shares outstanding, up 11.6% from the report before. At the average daily volume of 335,519 shares, buying them all back would take about 16.9 trading days (days to cover).

Shares short, % of all shares

28.4%May 15Oct 3030.4%

Days to cover

16.9May 15Oct 3030.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.69M28.41%+12%335,51916.9
Oct 15, 20265.09M25.45%+2%354,65014.4
Sep 30, 20264.97M24.86%+52%423,98911.7
Sep 15, 20263.28M16.39%+5%194,65716.9
Aug 31, 20263.14M15.67%+3%230,84113.6
Aug 14, 20263.04M15.18%+1%180,80316.8
Jul 31, 20263.01M19.30%+3%186,06616.1
Jul 15, 20262.93M18.80%-13%386,8937.6
Jun 30, 20263.35M21.52%-6%248,66213.5
Jun 15, 20263.55M22.78%+0%154,68422.9
May 29, 20263.55M22.77%-2%129,04527.5
May 15, 20263.60M23.14%-3%146,19724.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Neurogene company events

Neurogene filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 11, 2026ResultsReleased financial results. Filing
  3. Jul 2, 2026AgreementNeurogene Inc. entered into an underwriting agreement with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC, as representatives of the underwriters named therein, to issue and sell 3,500,000 shares of the Company’s common stock at a public offering… Filing
  4. Jun 29, 2026AnnouncementThe Company also made publicly available a presentation announcing positive, updated clinical data from its Phase 1/2 trial evaluating NGN-401gene therapy for the treatment of females with Rett syndrome. Filing
  5. Jun 8, 2026AnnouncementShared information with investors. Filing
  6. Jun 4, 2026VoteReported shareholder vote results. Filing
  7. May 12, 2026ResultsReleased financial results. Filing
  8. Apr 20, 2026LeadershipThe Board of Directors of Neurogene Inc., upon recommendation of the Board's Nominating and Corporate Governance Committee, took action pursuant to the Company's Amended and Restated Bylaws to expand the Board to seven directors and appoint Christine Mikail, the Company’s President and Chief… Filing
  9. Mar 24, 2026ResultsReleased financial results. Filing
  10. Feb 26, 2026AnnouncementShared information with investors. Filing
  11. Jan 12, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Neurogene financials

Famous investors that hold NGNE

4 of the 50 well-known investors we track reported holding NGNE in their latest 13F filing. The largest position is Steve Cohen's, worth $6.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026238,967$6.6M0.0%+68%
Ken Griffin · Citadel AdvisorsQ3 202692,858$2.6M0.0%-77%
Israel Englander · Millennium ManagementQ3 202624,633$685K0.0%-42%
Jim Simons · Renaissance TechnologiesQ3 202610,205$284K0.0%-50%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named NGNE in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Baker Bros. Advisors LP13G/A5.0%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A1.5%
Nov 16, 2026Baker Bros. Advisors LP13G/A5.0%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A1.5%
Nov 16, 2026RTW Investments, LP13G/A9.3%
Nov 16, 2026Samsara BioCapital, L.P.13G/A9.0%
Nov 16, 2026RTW Investments, LP13G/A9.3%
Nov 16, 2026Samsara BioCapital, L.P.13G/A9.0%
Oct 7, 2026PRUDENTIAL FINANCIAL INC13G11.2%
Oct 7, 2026PRUDENTIAL FINANCIAL INC13G11.2%
Oct 6, 2026Jennison Associates LLC13G11.1%
Oct 6, 2026Jennison Associates LLC13G11.1%

Questions about Neurogene Inc. (NGNE) stock

Who owns the most NGNE stock?

The largest reported owner of Neurogene Inc. (NGNE) is Samsara Biocapital, LLC, with 11.0% of the company. In total, 113 funds and institutions reported holding NGNE at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are NGNE insiders buying or selling?

In the last 12 months, NGNE insiders reported no open-market purchases and 17 sales worth $1.1M. The latest trade was on Jul 7, 2026. See every trade.

What is the short interest in NGNE?

As of Oct 30, 2026, 5.69M NGNE shares were sold short, 28.4% of the shares outstanding, up 11.6% from the report before. At the average daily volume of 335,519 shares, buying them all back would take about 16.9 trading days (days to cover). See the history.

Which famous investors hold NGNE?

4 of the 50 well-known investors we track reported NGNE in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $6.6M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.